<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Shanghai Micurx Pharmaceutical Co., Ltd. Class A — News on 6ix</title>
    <link>https://6ix.com/company/shanghai-micurx-pharmaceutical-co-ltd-a</link>
    <description>Latest news and press releases for Shanghai Micurx Pharmaceutical Co., Ltd. Class A on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 08 Apr 2025 07:38:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/shanghai-micurx-pharmaceutical-co-ltd-a" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683647a878dffbe2df151cb9.webp</url>
      <title>Shanghai Micurx Pharmaceutical Co., Ltd. Class A</title>
      <link>https://6ix.com/company/shanghai-micurx-pharmaceutical-co-ltd-a</link>
    </image>
    <item>
      <title>MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025</title>
      <link>https://6ix.com/company/shanghai-micurx-pharmaceutical-co-ltd-a/news/micurx-15-clinical-preclinical-research-073800025</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-micurx-pharmaceutical-co-ltd-a/news/micurx-15-clinical-preclinical-research-073800025</guid>
      <pubDate>Tue, 08 Apr 2025 07:38:00 GMT</pubDate>
      <description>The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clinical microbiology, infectious diseases, and infection control, ESCMID Global serves as a pivotal platform for scientific exchange. Shanghai MicuRx Pharmaceutical Co., Ltd. (&quot;MicuRx&quot;, Stock Code: 688373) will present 15 new clinical and precli</description>
    </item>
    <item>
      <title>MicuRx Pharmaceutical: Contezolid Global Phase III Clinical Trial Safety and Efficacy Evaluation Endorsed by Data Monitoring Committee, Promising Prospects for Diabetic Foot Infection Treatment</title>
      <link>https://6ix.com/company/shanghai-micurx-pharmaceutical-co-ltd-a/news/micurx-pharmaceutical-contezolid-global-phase-104400487</link>
      <guid isPermaLink="true">https://6ix.com/company/shanghai-micurx-pharmaceutical-co-ltd-a/news/micurx-pharmaceutical-contezolid-global-phase-104400487</guid>
      <pubDate>Tue, 25 Feb 2025 10:44:00 GMT</pubDate>
      <description>Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. (&quot;MicuRx&quot;, 688373.SH) announced significant progress in its global multicenter Phase III clinical trial evaluating MRX-4 Injection followed by Contezolid Tablets for the treatment of DFI. The DMC has completed its first safety and efficacy assessment, confirming that the drug&apos;s safety and efficacy profiles meet favorable expectations and recommending the trial proceed as planned.</description>
    </item>
  </channel>
</rss>